Rhythm Pharmaceuticals Inc (RYTM) - Total Assets
Based on the latest financial reports, Rhythm Pharmaceuticals Inc (RYTM) holds total assets worth $481.19 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Rhythm Pharmaceuticals Inc shareholders equity for net asset value and shareholders' equity analysis.
Rhythm Pharmaceuticals Inc - Total Assets Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Rhythm Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Rhythm Pharmaceuticals Inc's total assets of $481.19 Million consist of 97.0% current assets and 3.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.3% |
| Accounts Receivable | $26.08 Million | 5.4% |
| Inventory | $25.75 Million | 5.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.32 Million | 1.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Rhythm Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Rhythm Pharmaceuticals Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rhythm Pharmaceuticals Inc's current assets represent 97.0% of total assets in 2025, a decrease from 99.7% in 2012.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 62.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 5.4% of total assets.
Rhythm Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Rhythm Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Rhythm Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.41 | 3.24 | 24.46 |
| Quick Ratio | 4.16 | 3.08 | 24.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $360.97 Million | $258.68 Million | $395.28 Million |
Rhythm Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Rhythm Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 42.37 |
| Latest Market Cap to Assets Ratio | 11.61 |
| Asset Growth Rate (YoY) | 22.7% |
| Total Assets | $481.19 Million |
| Market Capitalization | $5.59 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Rhythm Pharmaceuticals Inc's assets at a significant premium (11.61x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Rhythm Pharmaceuticals Inc's assets grew by 22.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rhythm Pharmaceuticals Inc (2012–2025)
The table below shows the annual total assets of Rhythm Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $481.19 Million | +22.67% |
| 2024-12-31 | $392.27 Million | +17.89% |
| 2023-12-31 | $332.75 Million | -13.00% |
| 2022-12-31 | $382.48 Million | +16.07% |
| 2021-12-31 | $329.52 Million | +76.15% |
| 2020-12-31 | $187.07 Million | -39.36% |
| 2019-12-31 | $308.52 Million | +18.57% |
| 2018-12-31 | $260.21 Million | +71.49% |
| 2017-12-31 | $151.74 Million | +1129.73% |
| 2016-12-31 | $12.34 Million | -66.90% |
| 2015-12-31 | $37.27 Million | +19113.92% |
| 2014-12-31 | $194.00K | -98.93% |
| 2013-12-31 | $18.19 Million | -3.89% |
| 2012-12-31 | $18.92 Million | -- |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, … Read more